Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bcd-264
- Development stage
- Phase 3
- Lead developer
- Biocad
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
BCD-264 is a monoclonal antibody developed as a biosimilar to daratumumab (brand name Darzalex). It targets CD38, a cell surface protein highly expressed on multiple myeloma cells. The mechanism of action involves inhibition of CD38, leading to antibody-dependent cell cytotoxicity and immunostimulatory effects. BCD-264 is being developed primarily for the treatment of relapsed and refractory multiple myeloma in patients who have previously received proteasome inhibitors and immunomodulatory drugs. The drug is administered intravenously and has reached Phase 3 clinical trials, with studies designed to confirm its comparability in efficacy and safety to Darzalex monotherapy[2][3][4][5][6][7].
- Other names
- daratumumab biosimilar
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on bcd-264.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bcd-264.